Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes

(2010) Cristina Teodosio et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis

(2009) Christian Baumgartner et al.   AMERICAN JOURNAL OF PATHOLOGY

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

(2009) K.-H. Lim et al.   BLOOD

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

(2009) Andres Forero-Torres et al.   BRITISH JOURNAL OF HAEMATOLOGY

Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo

(2009) B. Hirsch et al.   CURRENT DRUG TARGETS

Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients

(2009) Luis Escribano et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Variable presence ofKITD816Vin clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)

(2009) Karl Sotlar et al.   JOURNAL OF PATHOLOGY

CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells

(2008) Burkhard Hirsch et al.   AMERICAN JOURNAL OF PATHOLOGY

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

(2008) N. Harir et al.   BLOOD